Tarsons Products
Tarsons Products Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 5 strong
The short version
Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards. Tarsons expects strong revenue growth driven by ramped-up utilization of expanded capacities and commercialization of new products, especially from FY’28 onwards.
From Tarsons Products's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards.
- Domestic market growth targeted at 15%+ year-on-year, with strong Q1 FY’27 performance exceeding 15% growth.
- New Panchla and Amta facilities expected to contribute 20-25% of standalone revenues by FY’28.
- Cell culture and other new product lines projected to generate approximately INR 65-70 crores in revenue in FY’28.
- Exports showing a healthy recovery with 29% Y-o-Y growth in Q1 FY’27 and expected to be a key growth driver, especially through white-labeling.
- Long-term growth anticipated from greater international presence and integration with Nerbe’s business, including improved product portfolio and geographical expansion.
- The company aims for 20-25% overall growth combining about 15% from existing products and 5-7% from new products like cell culture lines.
- Margin improvement expected with better utilization and operating leverage as new capacities ramp up.
Profitability & Margins
See what Tarsons Products said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
- Remaining facility commissioning progressing as planned; trial runs underway; full commissioning expected during Q2 FY’27 with revenue contribution starting second half FY’27.
- No major new CAPEX plans for this year besides maintenance; annual maintenance CAPEX expected around INR 20-25 crores.
- Anticipate ramp-up revenues from new Panchla and Amta facilities contributing 20-25% to standalone revenues by FY’28.
- Entire 4-year CAPEX plan expected to enable incremental revenue around INR 400 crores on fixed asset turnover basis, with peak sales potential around INR 750-800 crores.
- No government grants or incentives engaged for Panchla and Amta CAPEX.
- Focus shifting from capacity creation to utilization and commercialization to drive sustainable growth.
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tarsons Products said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Export business inquiries are very promising and strong as long as the environment remains conducive to business.
- Logistics, transportation, and input costs are currently major hurdles, more than tariffs.
- The company experienced a significant benefit from shipments in the latest quarter, affecting revenue recognition, but shipment schedules remain beyond their control due to global logistic challenges.
- No specific current order book or pending orders figure is explicitly mentioned in the transcript.
- The management acknowledges volatile external environments impacting business but remains optimistic on growth.
- The focus is on building international market base and increasing market share, with some cautiousness due to external factors.
Tarsons Products — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹121 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tarsons Products Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental Ltd (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
- Prevest Denpro Ltd (Q1 FY27)
Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…
- Vasa Denticity Ltd (Q1 FY27)
Average order value increased by about 27% largely due to higher ticket-size products; order volume growth was around 8% (Page 6). Key concall takeaways from…
Frequently Asked Questions
What were Tarsons Products Q1 FY27 results?
Tarsons expects sustainable revenue growth driven by expanded capacities and new product launches, particularly from FY’28 onwards. Tarsons expects strong revenue growth driven by ramped-up utilization of expanded capacities and commercialization of new products, especially from FY’28 onwards.
What is Tarsons Products share price analysis?
Tarsons Products currently shows a below-average growth signal. The stock trades at a P/E of 155.0 with a market cap of ₹1,835 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products planning capital expenditure?
Currently in final phase of large-scale capacity expansion program with significant CAPEX already commissioned and operational.
Keep Tarsons Products on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.